Caribou Biosciences, Inc. (CRBU)
0.2931
-0.02
(-5.60%)
USD |
NASDAQ |
Nov 20, 10:36
Caribou Biosciences Cash from Investing (Quarterly) : 19.39M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 19.39M |
| June 30, 2026 | 18.94M |
| March 31, 2026 | 23.98M |
| December 31, 2025 | 17.97M |
| September 30, 2025 | 10.85M |
| June 30, 2025 | 24.04M |
| March 31, 2025 | 49.38M |
| December 31, 2024 | 15.93M |
| September 30, 2024 | 26.52M |
| June 30, 2024 | 21.20M |
| March 31, 2024 | 22.96M |
| December 31, 2023 | -31.47M |
| September 30, 2023 | -68.48M |
| June 30, 2023 | 11.06M |
| Date | Value |
|---|---|
| March 31, 2023 | 20.70M |
| December 31, 2022 | 1.17M |
| September 30, 2022 | -8.339M |
| June 30, 2022 | -13.97M |
| March 31, 2022 | -72.11M |
| December 31, 2021 | -173.96M |
| September 30, 2021 | -1.93M |
| June 30, 2021 | -0.484M |
| March 31, 2021 | -0.022M |
| December 31, 2020 | -0.60M |
| September 30, 2020 | -0.004M |
| June 30, 2020 | -0.053M |
| March 31, 2020 | 7.02M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | 0.00 |
| Vaxcyte, Inc. | 170.77M |
| Foghorn Therapeutics, Inc. | 24.19M |
| Bolt Biotherapeutics, Inc. | 4.00M |
| Connect Biopharma Holdings Ltd. | 1.517M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.52M |
| Cash from Financing (Quarterly) | 2.989M |
| Free Cash Flow | -92.99M |
| Free Cash Flow Per Share (Quarterly) | -0.2096 |
| Free Cash Flow to Equity (Quarterly) | -22.22M |
| Free Cash Flow to Firm (Quarterly) | -22.54M |
| Free Cash Flow Yield | -293.7% |